Actively Recruiting

Age: 18Years +
All Genders
NCT05375591

AI & Radiomics for Stratification of Lung Nodules After Radically Treated Cancer

Led by Royal Marsden NHS Foundation Trust · Updated on 2022-05-24

1000

Participants Needed

2

Research Sites

263 weeks

Total Duration

On this page

Sponsors

R

Royal Marsden NHS Foundation Trust

Lead Sponsor

I

Institute of Cancer Research, United Kingdom

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study will assess the utility of radiomics and artificial intelligence approaches to new lung nodules in patients who have undergone radical treatment for a previous cancer.

CONDITIONS

Official Title

AI & Radiomics for Stratification of Lung Nodules After Radically Treated Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Confirmed history of previous radically or curative-intent treated solid organ cancer within 10 years of new CT thoracic scan showing a new pulmonary nodule
  • Biopsy confirming previous malignancy with multidisciplinary team (MDT) consensus and successful remission after treatment, or MDT consensus confirming cancer and decision to treat with subsequent remission if biopsy not possible
  • Radical treatment for previous cancer defined as surgical resection, radical radiotherapy or stereotactic beam radiotherapy, radical chemotherapy, radical chemo-radiotherapy, or multi-modality treatment including any of these
  • New pulmonary nodule ground truth known by either 2-year stable or resolved scan data for benign disease, or progressive enlargement or number increase with MDT consensus determining metastatic disease or new primary malignancy
  • Biopsy confirmation of benign disease or malignancy where applicable
  • CT scan slice thickness 2.5mm or less
  • Nodule size 5mm or larger
Not Eligible

You will not qualify if you...

  • CT imaging older than 10 years
  • Non-solid hematological malignancies including leukemia
  • Cases of radically treated primary cancer with early oligometastatic recurrence treated radically

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

The Royal Marsden NHS Foundation Trust (Chelsea Site)

London, United Kingdom, SW3 6JJ

Actively Recruiting

2

Royal Brompton Hospital

London, United Kingdom, SW3 6NP

Actively Recruiting

Loading map...

Research Team

S

Sejal Jain

CONTACT

L

Laura Boddy

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here